Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12716792 | 1.00 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1HTR6LTA4HFYN | |
| SCHEMBL12716798 | 1.00 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1HTR6LTA4HFYN | |
| SCHEMBL12422035 | 0.97 | FYN (0.35) | L3MBTL3L3MBTL1HTR6LTA4HFYN | |
| SCHEMBL12422034 | 0.97 | FYN (0.35) | L3MBTL3L3MBTL1HTR6LTA4HFYN | |
| SCHEMBL12716816 | 0.97 | FYN (0.35) | L3MBTL3L3MBTL1HTR6LTA4HFYN | |
| SCHEMBL21363769 | 0.94 | — | — | |
| SCHEMBL25946269 | 0.94 | — | — | |
| SCHEMBL12717986 | 0.90 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1CYP2D6CYP3A4CYP2C19 | |
| SCHEMBL24700391 | 0.85 | ALDH1A1 (0.41) | L3MBTL3L3MBTL1HTR6LTA4HCYP3A4 | |
| SCHEMBL22995523 | 0.81 | ALDH1A1 (0.39) | L3MBTL3L3MBTL1HTR6CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223750-A1 | NITROGEN-CONTAINING BICYCLIC COMPOUND WHICH CONTAINS PYRIMIDINE | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| US-9988391-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2018-06-05 | — | — | US | disclosed |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-12-29 | — | — | US | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL3 1217/4885L3MBTL1 849/4885HTR6 3425/4885 |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL3 1217/4885L3MBTL1 849/4885HTR6 3425/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL3 1217/4885L3MBTL1 849/4885HTR6 3425/4885 |
| US-20160376283-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | L3MBTL3 3990/4885L3MBTL1 3836/4885HTR6 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.